TapImmune has signed a deal with non-profit development group Aeras for preclinical work on a tuberculous vaccine. TapImmune's technology is designed to make vaccines more effective by boosting antigen presentation through the use of the Transporter of Antigen Processing (TAP). Financial terms of the deal were not disclosed. Release